Brief: Protalix Biotherapeutics And Secarna Pharmaceuticals Enter Into Collaboration And Option Agreement
17/12/2025 11:54
Dec 17 (Reuters) - Protalix Biotherapeutics Inc PBDA.F: PROTALIX BIOTHERAPEUTICS AND SECARNA PHARMACEUTICALS ENTER INTO COLLABORATION AND OPTION AGREEMENT PROTALIX BIOTHERAPEUTICS INC - GRANTED EXCLUSIVE OPTION TO LICENSE COMPOUNDS Source text: ID:nPn40PdrRa Further company coverage: PBDA.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protalix Biotherapeutics
See all newsIsrael's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
Brief: Protalix Biotherapeutics And Secarna Pharmaceuticals Enter Into Collaboration And Option Agreement